PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

CTIS2025-521371-31-00

/ Not yet recruitingPhase 2IIT

PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial

Start Date01 Jan 2026

Sponsor / Collaborator

Assistance Publique Hopitaux De Paris

ChiCTR2500111048

/ Not yet recruitingPhase 3IIT

Vasopressor-Guided Individualized versus Fixed-Duration Hydrocortisone on Outcomes in Patients with Septic Shock: A Multicenter Randomized Non-Inferiority Trial

Start Date01 Nov 2025

Sponsor / Collaborator-

100 Clinical Results associated with Hydrocortisone Acetate

100 Translational Medicine associated with Hydrocortisone Acetate

100 Patents (Medical) associated with Hydrocortisone Acetate

1,976

Literatures (Medical) associated with Hydrocortisone Acetate

01 Oct 2025·Drug Testing and Analysis

Endogenous Nature of Hydrocortisone Acetate in Horse

Article

Author: Wong, April S. Y. ; Ho, Emmie N. M. ; Kong, Fred K. W. ; Wan, Terence S. M.

ABSTRACT:

Hydrocortisone acetate, a synthetic acetate ester of hydrocortisone, was detected in horse blood samples collected from Thoroughbreds. Hydrocortisone acetate is generally considered an indicator for exogenous administration in horses. As hydrocortisone acetate has been previously reported to be endogenous in selected mammals, a proof‐of‐concept study was performed to evaluate the possible endogenous nature of hydrocortisone acetate in horses by in vitro incubation experiments using homogenized horse brain tissue.

01 Jun 2025·CHEMICAL ENGINEERING JOURNAL

Optimizing pyrolysis of herbal tea and Salvia miltiorrhiza residues for sustainable energy and product recovery

Author: Lin, Ziting ; Huang, Wenxiao ; Evrendilek, Fatih ; Li, Weixin ; Chen, Xin ; He, Yao ; Li, Liangzhong ; Yang, Zuoyi ; Chen, Yan ; Yang, Chunxiao ; Liu, Jingyong ; Zhong, Sheng

With the global shift to renewable energy and a circular economy, the pyrolysis of traditional Chinese medicine residues offers a promising alternative for resource recovery.This study characterized the pyrolysis behaviors and products of herbal tea residues (HBR) and Salvia miltiorrhiza residues (SMR) in the N₂ and CO₂ atmospheres.A three-stage pyrolysis process was identified for both fuels, with the primary reaction occurring between 180-620°C for HBR and 170-600°C for SMR.Kinetic anal. demonstrated that CO₂ reduced the activation energy of pseudo-components in HBR but increased it for SMR.Under N₂, slow pyrolysis produced eicosane (C₂₀H₄₂) as the main product for HBR (32.90%) and dodecanoic acid (C₁₂H₂₄O₂) for SMR (26.61%).In CO₂, 1-nonadecene (C₁₉H₃₈) was the primary product for HBR (45.22%), and 1-tetradecanol (C₁₄H₃₀O) for SMR (42.17%).Fast pyrolysis in N₂ predominantly produced acetic acid (C₂H₄O₂) for both HBR (16.40%) and SMR (18.70%).These findings offer new insights into the valorization of both fuels as a sustainable energy source and provide a basis for further exploring their scalability and economic feasibility.

01 Jun 2025·JOURNAL OF HAZARDOUS MATERIALS

Pollution characteristics, sources and ecological risks of steroid hormones in Fangchenggang Bay, South China Sea: Significant impacts of rivers and domestic sewage entering the sea

Article

Author: Fang, Qin ; Ren, Chaoxing ; Long, Huiqin ; Liu, Fangfang ; Gao, Guilan ; Lan, Wenlu

The characteristics, sources and ecological risk of steroid hormone pollution were investigated at 14 stations in Fangchenggang Bay. The results revealed that the detection rate of the steroid hormones in both seawater and sediment was 100 %. Twenty-four types of steroid hormones were detected in seawater, and the concentrations ranged from 0.05 (P) to 7.40 ng/L (HCT). Seventeen types of steroid hormones were detected in marine sediments, and the concentrations ranged from 0.02 (SZL) to 0.82 ng/g (E3). The monthly contributions of rivers flowing into the sea and domestic sewage treatment plants were 2178.2 kg and 46.03 kg, respectively. Based on the ecological risk assessment results, MT and EE2 in seawater were considered to be at high risk level, and E2α was at medium risk, whereas the others were considered to be low or no risk levels; in marine sediments, MT, E2αand EE2 were at a high risk level; AED, E1, E2 α, and E3 were at a medium risk level; and the others were at low or no risk levels. The steroid hormones in the monitoring area were mainly affected by land-based pollution. This issue warrants immediate attention from the relevant management departments, and effective preventive measures need to be performed.

News (Medical) associated with Hydrocortisone Acetate

26 Oct 2025

·www.prnewswire.com

Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppository Applicator Demonstrates Statistically Significant Rates of Clinical Remission in Patients with UC in CESSA Phase 3 Trial Additional Findings Reinforce Rapid and Sustained Drug Release of ngHCA AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is presenting three posters highlighting pivotal new data in ulcerative colitis (UC) of the rectum research at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Arizona. "We are excited to present Cristcot's data at ACG 2025, which showcases our meaningful contributions across the spectrum of UC research and reinforces the transformative potential of our ngHCA suppository - the first investigational agent to show rapid clinical remission in UC," said Jennifer J. Davagian, Founder and Chief Executive Officer, Cristcot. "As we progress towards FDA submission and commercialization of our novel therapy, we are focused on close collaboration with the gastroenterology community through forums like ACG to ensure we are best positioned to address the needs of patients, providers, and payers in this field. We look forward to continuing to advance our innovative, patient-centric solutions." ACG Presidential Poster Distinction Recognizes Excellence in Clinical Research The CESSA abstract was selected as an ACG 2025 Presidential Poster Recipient among nearly 6,000 abstracts. The distinction is reserved for approximately five percent of submissions and recognizes high-quality, novel, and clinically meaningful research contributing to advances in gastroenterology. Pivotal Phase 3 CESSA Trial Poster Title: Efficacy and Safety of a Novel Investigational Hydrocortisone Acetate Suppository Formulation and Optimized Applicator for Treatment of Active Ulcerative Colitis: Results of the Phase 3 CESSA Trial Key Findings: The Phase 3 CESSA trial evaluated efficacy and safety of Cristcot's ngHCA 90 mg suppository administered with the proprietary Sephure® suppository applicator in adults with confirmed active moderate to severe UC. Efficacy The trial achieved its primary endpoint of clinical remission at Day 29 and secondary endpoint of clinical response at Day 15, both using modified Mayo Score (MMS) criteria, demonstrating statistically significant improvements for patients treated with the ngHCA 90 mg suppository compared to those who received placebo. Clinical and endoscopic remission was achieved by 21.2% (p=0.0005) of study participants in the ngHCA QD (once-daily) arm versus 1.5% of patients in the placebo arm. Secondary efficacy analyses showed that treatment with ngHCA QD resulted in greater improvement in rectal bleeding and stool frequency scores at Day 15 and Day 29 versus placebo. Concomitant medication for UC (stable dose) was taken by 63.5% of patients throughout the study. No non-study corticosteroids were permitted. Safety and Compliance ngHCA was well tolerated. There were no treatment-related serious adverse events (SAEs). Treatment-related adverse events (TEAEs) were reported by 4.5% of patients in the QD treatment group and 7.6% in the placebo group. The majority of TEAEs were mild and moderate in severity. Compliance was very high - 100% of subjects in the ngHCA QD group had greater than 90% adherence with the required dosing. Additional details on the CESSA trial can be found in Cristcot's January 2025 press release, available on the News page of its website. "There is an urgent need for a fast-acting, localized, and easy-to-administer option to manage patients with active ulcerative colitis," said Raj Devarajan, MD, Global Medical Advisor, Cristcot, and presenting author. "I'm thrilled to share the pivotal CESSA trial results as a Presidential Poster at ACG, which marks a meaningful advancement in this area. The efficacy demonstrated in CESSA, notably clinical responses within two weeks and endoscopic remission by four weeks, has never been achieved in the moderate to severe UC population. Combined with a favorable tolerability profile, these data support this novel HCA combination product to treat UC exacerbations alongside maintenance therapies or as a monotherapy. I look forward to its continued evaluation as a new option for the many patients who continue to face gaps in effective management of this disease." Innovation in Pharmacokinetics Title: Pharmacokinetics and Relative Bioavailability of an Investigational Hydrocortisone Acetate Suppository Administered with a Novel FDA-Cleared Applicator Versus Hydrocortisone Liquid Enema Key Findings: In this Phase 1 study, the ngHCA suppository administered using the Sephure® suppository applicator demonstrated sustained release with optimal bioavailability that is expected to provide consistent efficacy over the intended treatment period. New Data Highlights: Clinical Trial Methodology Title: Recent Recall as an Alternative to Daily Study Participant Diaries in Ulcerative Colitis Trials: Evidence from a Phase 3 Clinical Trial Key Findings: This prespecified exploratory analysis from the Phase 3 CESSA trial demonstrated that participant-reported UC symptom data collected through recent (3-day) recall correlated with data collected through daily participant diaries. These findings indicate that recent recall offers a reliable, lower-burden alternative to daily diaries for collecting patient-reported outcomes in future UC trials. Cristcot's presence at ACG 2025 underscores its commitment to advancing evidence-based, patient-focused solutions that address persistent gaps in ulcerative colitis care. Additional information, including abstracts, can be found on the ACG 2025 Annual Meeting website. About Cristcot's HCA 90 mg Suppository Cristcot's investigational hydrocortisone acetate (HCA) 90 mg suppository formulation is a novel corticosteroid therapy delivering a small volume suppository using the Sephure® applicator to ensure precise placement, minimizing discomfort and leakage. Rectally administered topical treatments, including topical corticosteroids, are important treatment options (either alone or in combination with other therapies), for directing delivery to inflammation sites and limiting systemic drug exposure, though there is no FDA-approved corticosteroid suppository on the market. Unlike traditional corticosteroid treatments, Cristcot's advanced HCA formulation allows for rapid, sustained release with optimal bioavailability, consistent and localized efficacy, and very limited systemic exposure. The innovative delivery system may enhance patient compliance. About Ulcerative Colitis UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms often include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients' quality of life. UC flares frequently originate in the rectum, and untreated inflammation can progress to more extensive disease, leading to hospitalization or surgery. There is no cure for UC and, breakthrough flares, even while taking maintenance medication, is a known characteristic of the disease profile. Over 55% of UC patients experience 3-5 flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential. Gaps remain in addressing flares quickly and effectively, highlighting the need for targeted therapies that can provide rapid symptom relief and remission. About Cristcot Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company's lead asset, a novel hydrocortisone acetate suppository, is positioned to become an important therapeutic option for ulcerative colitis. Cristcot's diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Austin, Texas. For more information, please visit and connect with us on LinkedIn. Forward-Looking Statements Certain information set forth in this press release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Examples of forward-looking statements include, but are not limited to, statements regarding the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company's products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company's products; (vi) execution of the Company's vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. Contacts Jenny Gizzi, Chief Administrative Officer Cristcot [email protected] Tanner Kaufman / Katie Harris FTI Consulting [email protected] / [email protected] SOURCE Cristcot WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

24 Jun 2025

·www.prnewswire.com

Cristcot Highlights Engagement with GI Community at 2025 GI ReConnect Annual Meeting

Company Builds on Late-Stage Clinical Progress and Continues Momentum in Ulcerative Colitis CONCORD, Mass., June 24, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, participated in the 5th annual GI ReConnect meeting in Aurora, Colorado, as a Gold Sponsor. The conference convened leading gastroenterologists from academic institutions and community practices across the country to explore evolving approaches in gastroenterology (GI) care. During the conference, Cristcot hosted a dedicated medical exchange meeting with GI thought leaders to discuss current trends in ulcerative colitis (UC) treatment and highlight progress on its pivotal, Phase 3 CESSA study for the treatment of UC. The Company has continued to receive strong positive feedback as it advances its novel investigational hydrocortisone acetate (HCA) 90 mg suppository administered with Cristcot's proprietary Sephure® suppository applicator, towards commercial approval and launch. In the coming year, the Company plans to continue its meaningful engagement with the clinicians who are shaping the future of care and treatment for UC patients. "We were thrilled to sponsor this year's GI ReConnect and continue to receive support from esteemed colleagues and thought leaders in gastroenterology on our efforts in addressing the needs of UC patients," said Jennifer J. Davagian, Founder and Chief Executive Officer, Cristcot. "Currently the Company is in a period of immense momentum as we work to advance our late-stage UC program and continue to foster our deep partnerships with the GI community. Events like this help ensure our mission alignment with the real world needs of patients and providers as we pursue our maturing clinical pipeline." "The GI ReConnect forum provides a unique opportunity for thoughtful, real-time dialogue between companies developing new therapies and the physicians who ultimately bring those therapies to patients," said Raj Devarajan, MD, Global Medical Advisor, Cristcot. "Hearing firsthand from leading gastroenterologists about trends in UC care provides essential information to inform and strengthen the Company's clinical strategies and ensure we are focused on the latest developments for patients in need of new solutions." Cristcot's participation in GI ReConnect is part of the Company's broader effort to expand its presence and partnerships within the field of gastroenterology. The Company plans to attend several additional GI-focused scientific meetings in 2025. About Cristcot's HCA 90 mg Suppository Cristcot's investigational HCA 90 mg suppository formulation is a novel therapy delivered using the Sephure® suppository applicator, the small-volume suppository ensures precise placement, minimizing discomfort and leakage. This innovative delivery system may enhance patient compliance. Unlike traditional corticosteroid treatments, the suppository's differentiated mechanism of action allows for rapid release and localized efficacy, reducing systemic exposure. About Ulcerative Colitis UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms often include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients' quality of life. UC flares originate in the rectum, and untreated inflammation can progress to more extensive disease, leading to hospitalization or surgery. There is no cure for UC and, breakthrough flares, even while taking maintenance medication, is a known characteristic of the disease profile. Over 55% of UC patients experience 3-5 flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential. Gaps remain in addressing flares quickly and effectively, highlighting the need for targeted therapies that can provide rapid symptom relief and remission. About Cristcot Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company's lead asset, a novel hydrocortisone acetate suppository, is positioned to become the first line therapy for ulcerative colitis. Cristcot's diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Concord, Massachusetts. For more information, please visit and connect with us on LinkedIn. Forward-Looking Statements Certain information set forth in this press release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Example of forward-looking statements include, but are not limited to, the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company's products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company's products; (vi) execution of the Company's vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. Contacts Jenny Gizzi, Chief Administrative Officer Cristcot [email protected] Tanner Kaufman / Shana Marino FTI Consulting [email protected] / [email protected] SOURCE Cristcot WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

04 Feb 2025

·www.businesswire.com

Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study

QUEBEC CITY--( BUSINESS WIRE )--Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the results of its in vitro comparative study, which demonstrate the anti-inflammatory effect of Thykamine™, with superior potency on the inflammatory biomarkers as compared to currently marketed anti-inflammatory agents, which included various corticosteroids and a phosphodiesterase inhibitor. The assays were conducted at Department of Microbiology, Infectious Diseases, and Immunology in the Faculty of Medicine at Université Laval (Quebec City) under the leadership of Pr Louis Flamand, PhD, MBA (1) in collaboration with Dr John Sampalis, PhD, Epidemiologist, Medicine Faculty, McGill University and Dr Charles Lynde, MD from Lynde Dermatology and Associate Professor in the Department of Medicine at the University of Toronto. The primary objective of the study was to compare the anti-inflammatory potency of Thykamine™ to other anti-inflammatory agents in the market, specifically betamethasone valerate, clobetasol, crisaborole, 21-acetate hydrocortisone, pimecrolimus and prednisone. The experiment involved treating lipopolysaccharide (LPS) stimulated U937 monocytic cells with each agent. Anti-inflammatory potency was assessed by the percent inhibition of the activity of four cytokines induced by each agent. The four cytokines tested were MCP-1, MIP-1α, MIP-1β and RANTES that have been implicated in several autoimmune diseases. Percent inhibition was calculated as the reduction in lipopolysaccharide (LPS) induced cytokine activity after addition of the agent. Given that the aim of anti-inflammatory drugs is to dampen cytokine induced inflammation, these results can be used as inference to overall anti-inflammatory efficacy. All agents were tested at four increasing concentrations except for pimecrolimus that was tested at three concentrations. All culture conditions were run in hexaplicate (n=6). Cell-free supernatants were collected and immediately assayed for cytokine concentration using Pro-Carta 6 plex (Life Technologies). U937 secreted amounts of IL-6 or IL-10 that were below the detection limits of the assay and were not included in the analyses. When compared to the other agents, Thykamine™ showed clinically important and statistically significant higher inhibition potency for MCP-1 (by 28% to 136%; P< 0.009), MIP-Alpha (by 30% to 108%; P < 0.001), MIP-1 Beta (by 39% to 111%; P < 0.001). For RANTES higher inhibition was observed for all agents (by 47% to 258%) except for Crisaborole and Prednisone. In this assay, pimecrolimus did not inhibit any of the cytokine tested. “ These results support the wide spectrum anti-inflammatory properties of Thykamine™ with potency that is superior to currently marketed anti-inflammatory agents. This study indicates a multi mode of action of Thykamine™ affecting several cytokines and other biomarkers, supporting the clinical efficacy demonstrated in phase 2 studies in ulcerative colitis and atopic dermatitis in adults,” said Dr Louis Flamand, lead study investigator. “ The high potency and previously established clinical efficacy of Thykamine™ , combined with its placebo-like safety, should compel practitioners to consider its use as a first line treatment, especially with the potential safety concerns of the present standard of care,” said Dr Lynde, who was consulted on the current study and was the lead investigator in Devonian’s phase 2 study in adults with mild-to-moderate atopic dermatitis. The study’s co-investigator Dr. John Sampalis, Clinical Epidemiologist, and Professor of Medicine at McGill with extensive experience in the evaluation of treatments for autoimmune disorders commented: “ The results of this in vitro study are extremely encouraging. The favorable safety profile of Thykamine™ as demonstrated in human clinical studies and its high anti-inflammatory potency proven in this study, would position Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease. This can result in steroid sparing effect and reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences.” Investigators of this study are planning to submit the results in a peer-reviewed journal. (1) Pr. Louis Flamand is a director on the board of directors of the Corporation About Thykamine™ Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North America, Europe and Asia. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit www.groupedevonian.com Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economical impact of clinical study, the efficiency of the high anti-inflammatory potency proven and the position of the Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease and the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Phase 2Clinical Result

100 Deals associated with Hydrocortisone Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00165	-	-	DB14539

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis	Australia	Aspen Pharmacare Australia Pty Ltd.	14 Oct 1991
Eczema	Australia	Aspen Pharmacare Australia Pty Ltd.	14 Oct 1991
Ulcerative proctitis	United States	Mylan Specialty LP	10 Feb 1982
Colitis, Ulcerative	United States	Merck & Co., Inc.	21 Dec 1951
Skin Diseases	United States	Merck & Co., Inc.	21 Dec 1951

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00136435 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia	100	L-asparaginase	wdidksmxwh = nsickimjfc huvzvdirhd (dndfyqsmrj, fbcbkehgau - qxsrfuqctz) View more	-	20 Oct 2025
NCT02700828 (CORTISoL, Pubmed \| J Perinatol)	Phase 2/3	Neonatal encephalopathy	55	Hydrocortisone	zjvgfuueyl(skisxsuamq): P-Value = 0.13	Negative	22 Sep 2025
				Placebo
NCT03718234 (CTgov)	Phase 1	Adrenal Hyperplasia, Congenital \| Adrenocortical Hyperfunction \| Hyperplasia	11	Subcutaneous hydrocortisone	bdelmgfaot(tcwrlwdaxy) = kgtzlklrfy pybeywvbvt (qwkhnagelv, 9.96) View more	-	25 Jun 2025
NCT00623740 (EudraCT number 2007-002041-20, Pubmed \| Eur J Pediatr)	Phase 3	Obstetric Labor, Premature	-	Prophylactic hydrocortisone	ylvhtevbxu(jivvpstyco) = dpmpvljzmh eoaleasdob (yrycfjqcwp )	Negative	14 Jun 2025
				Placebo	ylvhtevbxu(jivvpstyco) = qfpasnxjzo eoaleasdob (yrycfjqcwp )
NCT00001521 (CTgov)	Phase 3	Adrenal Hyperplasia, Congenital \| Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	66	Fludrocortisone+Letrozole+Testolactone+Flutamide+Hydrocortisone (Investigational Therapy)	nqjpjukafz(aynmzxfptd) = vyyupwryzr lgqbifvuso (dpooahysvi, 0.93) View more	-	12 Jun 2025
				Fludrocortisone+Hydrocortisone (Standard Therapy)	nqjpjukafz(aynmzxfptd) = ieugswdtdc lgqbifvuso (dpooahysvi, 0.89) View more
cessa (PRNewswire) Manual	Phase 3	Ulcerative proctitis	171	Hydrocortisone Acetate Suppository 90mg QDHydrocortisone Acetate Suppository 90mg QD	leuxegdnto(wodafwamku) = trzkvpzuis czyqmlmsks (uxajnhfcdq ) Met	Positive	09 Jan 2025
				Hydrocortisone Acetate Suppository 90mg BIDHydrocortisone Acetate Suppository 90mg BID	leuxegdnto(wodafwamku) = dieanhnbwm czyqmlmsks (uxajnhfcdq ) Met
NCT03062280 (CTgov)	Phase 3	Adrenal Hyperplasia, Congenital	91	Hydrocortisone	qwbinvsird = elfpujkftu yspnkuvody (kzdsnalouy, upxhqywsnw - qgqvmtkrld) View more	-	24 Oct 2024
NCT03792256 (CTgov)	Phase 1	Recurrent Adult Acute Lymphoblastic Leukemia \| T-Cell Lymphoma \| acute leukemia ... View more	12	ARAC (Stratum 1 With 50 mg/m^2)	edbkinqegz = dlbkckvcni pmicuixkyu (raslrjjlsh, clzysxxtwe - tjmuyonspc) View more	-	16 Aug 2024
				ARAC (Stratum PK With 50 mg/m^2)	edbkinqegz = qtxhkfgvnj pmicuixkyu (raslrjjlsh, usuqfcajwe - izlsabdykb) View more
NCT00859781 (CTgov)	Phase 2	Non-metastatic prostate cancer	55	111In-J591+Ketoconazole+Hydrocortisone	kqvituzrcw = ajqiprslhn rfwjkppzhq (jvfddllgip, jdyvhvxzni - ecufjwhwqa) View more	-	19 Jul 2023
NCT02517489 (CAPE COD, Pubmed)	Phase 3	Community Acquired Pneumonia	800	Hydrocortisone	egfcxbjjvc(lmgihufdma) = cixcjwrnqg xstgygyvww (ouskfsjych, 3.9 - 8.6) View more	Positive	21 Mar 2023
				Placebo	egfcxbjjvc(lmgihufdma) = tvnlcfjfho xstgygyvww (ouskfsjych, 8.7 - 15.1) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrocortisone Acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation